Ceretas Ltd · ASX:CTS
Ceretas — Investor Presentation (October 2026)
19 slides from Ceretas's investor presentation, Oct 19, 2026
Slide 1: Building the world's first portable, clinic-ready therapeutic ultrasound for Alzheimer's
ASX: CTS rsonal use only Building the world’s first portable, clinic-ready therapeutic ultrasound for Alzheimer’s disease Investor Presentation - October 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Ceretas Limited and its related entities Australian state or territory legislation (or the law of any similar legislation in any (the “Company”) and is not an offer document. It does not purport to contain all other jurisdiction), or similar provisio
Slide 3: Corporate Overview
Corporate Overview Corporate snapshot (ASX:CTS) Management and Board Shares on issue 71,375,000 Dr Rachel de las Heras CEO and Managing Director rsonal use only Previously led ultrasound product development at UQ/QBI Options on issue1 9,580,000 Dr Tony Keating Executive Director Performance rights2
Slide 4: Company Overview
Company Overview The First Portable Therapeutic Ultrasound for Alzheimer’s rsonal use only No broadly available therapy exists for the 57 million people living with Alzheimer's and related dementias, with 10 million new cases added every year 1 A Novel Therapeutic Modality Our device uses ultrasound
Slide 5: Alzheimer's devastates patients, families and healthcare systems
Alzheimer’s devastates patients, families and healthcare systems A defining healthcare crisis rsonal use only Alzheimer’s erodes memory, language and reasoning US$2.8T estimated annual worldwide cost of dementia by 2030 1 57 million people live with dementia today, As cognition declines, patients lo
Slide 6: Success of current drug therapies is limited
Success of current drug therapies is limited Treating cognition in early-stage Alzheimer’s Treating agitation associated with Alzheimer’s rsonal use only Target and remove amyloid-β plaques in the brain Modulate serotonin and dopamine neurotransmission to reduce agitation • Modest clinical benefits
Slide 7: Diagnostic ultrasound sees tissue, therapeutic ultrasound changes it
Diagnostic ultrasound sees tissue Therapeutic ultrasound changes it rsonal use only Diagnostic Ultrasound Therapeutic Ultrasound Disease modifying potential Preclinical studies have shown ultrasound improves memory and cognition through direct brain stimulation and separately clears amyloid and tau
Slide 8: One device, two ways to treat Alzheimer's
One device, two ways to treat Alzheimer’s Neuromodulation Blood-brain barrier opening rsonal use only Delivers ultrasound stimulation to targeted brain regions, modulating neural activity Uses ultrasound and microbubbles to transiently open by restoring synaptic plasticity and promoting neurogenesis
Slide 9: Clinical Programs
Clinical Programs FIRST-IN-HUMAN SAFETY FEASIBILITY TRIAL PIVOTAL TRIAL DEVICE MODE INDICATION OVERVIEW PRECLINICAL (PHASE 1) (PHASE 2) (PHASE 3) SPONSOR rsonal use only Commencing in H2 2026 Neuromodulation Behavioural & Ceretas-led trial to treat Psychological BPSD in mild-moderate Symptoms in Alz
Slide 10: Phase 2 Feasibility Trial: Patient Journey
Phase 2 Feasibility Trial: Patient Journey Randomised 2:1, double-blind and sham (placebo)-controlled, 60 participants rsonal use only Active treatment arm Measure NPI Compare change in Recruit 4 NPI weekly 30 minute (active vs sham) patient with Patient 2 weeks Measure neuromodulation Alzheimer’s r
Slide 11: Phase 2 Feasibility Trial: Details
Phase 2 Feasibility Trial: Details Two complementary trials targeting two distinct brain regions with two potential outcomes rsonal use only Ceretas-led Phase 2 Feasibility Trial Investigator-led Phase 2 Feasibility Trial Sponsor Ceretas The University of Queensland Funding Ceretas, fully-funded fro
Slide 12: Competitive Landscape
Competitive Landscape Ceretas’s device brings the advantages of focused ultrasound to Alzheimer’s, without the cost and bulk of other approaches rsonal use only Essential Tremor, Epilepsy, Brain Alzheimer’s Alzheimer’s Alzheimer’s Alzheimer’s Primary Indication(s) Parkinson’s tumours BPSD & Cognitio
Slide 13: Commercial Model
Commercial Model Device sales into aged care facilities, Biopharma collaboration for drug rsonal use only neurology and geriatrician clinics with delivery recurring subscription revenue • Upfront capital equipment sale to the • Over 98% of potential CNS drugs cannot cross clinic or facility the bloo
Slide 14: Milestones & Near-term Catalysts
Milestones & Near-term Catalysts A steady run of clinical, device and regulatory catalysts through to 2028 H2 2026 Mid-2027 2027 H1 2028 2028 rsonal use only First patients in both Phase 2 Next-gen device complete BBBO preclinical data Both Phase 2 trials complete BBBO first-in-human trials; FDA pre
Slide 15: Contact Details
rsonal use only Contact Details Rachel de las Heras Chief Executive Officer & Managing Director [email protected] Tony Keating Executive Director [email protected] Henry Jordan Six Degrees Investor Relations [email protected]
Slide 16: Appendix A. Neuromodulation preclinical data
Appendix A. Neuromodulation preclinical data Neuromodulation restores synaptic plasticity and promotes neurogenesis (improving the brain’s ability to form and repair connections). rsonal use only Low-intensity ultrasound restores long-term potentiation and memory in Scanning ultrasound-mediated memo
Slide 17: Appendix B. Neuromodulation Phase 1 safety data
Appendix B. Neuromodulation Phase 1 safety data Neuromodulation found to be safe and tolerable in humans with promising early efficacy signal in BPSD without needing to clear amyloid and tau rsonal use only A pilot safety and tolerability study of scanning ultrasound as a Primary endpoint (safety an
Slide 18: Appendix C. BBBO preclinical data
Appendix C. BBBO preclinical data Ultrasound with microbubbles enables removal of amyloid & tau build-up through microglial activation & autophagy (brain’s own protein removal systems) rsonal use only Amyloid clearance through microglial activation Tau clearance through autophagy in neurons Scanning
Slide 19: Appendix D. Ceretas Management & Board
rsonal use only Appendix D. Ceretas Management & Board Dr Rachel de las Heras Dr Tony Keating Al Rey Lunar Vesa Peltonen CO-FOUNDER & CEO EXECUTIVE DIRECTOR CHIEF FINANCIAL OFFICER CHIEF TECHNICAL OFFICER 20 years in medical device Co-founder and CEO of Seasoned finance executive Technical executive